Skip to content
Research Article Open access CC BY 4.0

Association of Serum Soluble Endoglin Levels with Adverse Foetomaternal Outcome in Preeclampsia and Eclampsia

Rekha Sachan, Munna Lal Patel, Pratima Verma, Soniya Dheeman, Pooja Gupta

Journal of Advances in Medicine and Medical Research · pp. 1–9 · Published 18 Oct 2016

10.9734/BJMMR/2016/28862

Abstract

Background: Serum Endoglin has also previously shown to be elevated in woman with established preeclampsia especially in those presenting with preterm labour and foetal growth retardation. Objectives: To evaluate association of serum soluble Endoglin with adverse foeto-maternal outcome in woman with hypertensive disorders of pregnancy. Materials and Methods: A prospective case control study carried out from 2013 to 2014 at department of Obstetrics and Gynaecology. Ethical clearance was obtained from institutional ethics committee No.ECR/262/Inst/UP/2013 from King Georges Medical University, Lucknow. After informed consent, total 90 pregnant women from gestational age 20-40 weeks were enrolled after randomization. 30 women of preeclampsia and 30 of antepartum eclampsia served as cases where as 30 normotensive pregnant women served as controls. Preeclampsia was defined as per NHBPEP2000 working group. Estimation of serum soluble Endoglin level was done by Enzyme linked immunosorbent assay using ELISA kit. Results: Serum Endoglin levels were found higher in preeclampsia and eclampsia group (p<0.001) in comparison to controls. The women who had complication in terms of postpartum haemorrhage, cerebrovascular accident during the study had maternal serum Endoglin levels 12.48 ng/ml, and 16.08 ng/ml, respectively in preeclampsia group and 15.88 ng/ml, 16.76 ng/ml respectively in eclampsia group. 4 women expired, all were from eclampsia group mean serum Endoglin level of these women was 14.18±2.4. Serum Endoglin levels increased with low birth weight in preeclampsia and eclampsia. 12 neonates in preeclampsia and 17 neonates in eclampsia, required admission to NICU, in whom the maternal serum Endoglin level was 14.67±1.77, 15.68±1.48 respectively, which was higher than those neonates who did not required admission & difference was statistically significant (p<0.001). Neonates who died had high maternal S. Endoglin level (15.77±0.44 and 16.23±1.30) as compared to alive foetuses (12.35±2.49, 14.30±1.86 respectively). Conclusion: Serum soluble Endoglin level might predict adverse foetomaternal outcome, but larger studies should be carried out to confirm this association.

Serum endoglin preeclampsia eclampsia pregnancy outcome fetal outcome

References (16)

  1. 1 Soluble endoglin contributes to the pathogenesis of preeclampsia [DOI]
  2. 2 Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia [DOI]
  3. 3 Balancing the activation state of the endothelium via two distinct TGF‐β type I receptors [DOI]
  4. 4 Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia [DOI]
  5. 5 Preeclampsia and Angiogenic Imbalance [DOI]
  6. 6 Acute renal failure in pregnancies complicated by hemolysis, elevated liver enzymes, and low platelets [DOI]
  7. 7 Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia [DOI]
  8. 8 Current CHS and NHBPEP Criteria for Severe Preeclampsia Do Not Uniformly Predict Adverse Maternal or Perinatal Outcomes [DOI]
  9. 9 Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy [DOI]
  10. 10 Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia [DOI]
  11. 11 Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia [DOI]
  12. 12 Soluble endoglin contributes to the pathogenesis of preeclampsia [DOI]
  13. 13 Severe preeclampsia and eclampsia in Kerman, Iran: complications and outcomes.
  14. 14 Outcomes in hypertensive disorders of pregnancy in the North Indian population [DOI]
  15. 15 HYPERTENSION AND PREGNANCY-RELATED HYPERTENSION [DOI]
  16. 16 Hypertensive disorders of pregnancy and maternal and foetal outcome: a case controlled study.

Cited by 1

Soluble endoglin as a biomarker for risk of stillbirth in pregnancies with pregnancy induced hypertension: A case-control study

Sanyukta Patil, M. Somannavar, D. Sadanandan · Indian Journal of Obstetrics and Gynecology Research · 2025

Related research

Article metrics

Real usage data collected on this platform.

60

Page views

0

PDF downloads

32

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.